Vext Science Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Vext Science has been growing earnings at an average annual rate of 1.2%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 10.5% per year.
Belangrijke informatie
1.2%
Groei van de winst
-2.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 10.5% |
| Rendement op eigen vermogen | -8.0% |
| Nettomarge | -20.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks
Oct 24
Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper
Jun 18There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding
Jan 16Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?
Sep 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Jan 17Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now
Dec 09We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt
Sep 29Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly
Apr 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Nov 15Is Vext Science (CSE:VEXT) A Risky Investment?
Jul 15Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)
Apr 25Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?
Jan 15Opbrengsten en kosten
Hoe Vext Science geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -7 | 16 | 0 |
| 31 Mar 24 | 34 | -2 | 14 | 0 |
| 31 Dec 23 | 35 | 4 | 14 | 0 |
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 9 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
Kwaliteitswinsten: VEXT is currently unprofitable.
Groeiende winstmarge: VEXT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VEXT is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
Versnelling van de groei: Unable to compare VEXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: VEXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: VEXT has a negative Return on Equity (-7.97%), as it is currently unprofitable.